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ABSTRACT
Objectives: The principal aim of this study was to illustrate
applying discrete-choice methods for eliciting preferences for
technology adoption criteria, including threshold values for
cost-effectiveness ratios. A secondary objective was to com-
pare the criteria weights of a sample of industry stakeholders
with the results obtained from a study of National Institute
for Health and Clinical Excellence (NICE) recommenda-
tions.
Methods: We administered a two-stage stated-preference
(SP) question format to a sample of respondents who have
expertise in applying economic analysis to technology adop-
tion decisions. We elicited paired comparisons and recom-
mendation judgments for similar criteria from a sample of
International Society for Pharmacoeconomics and Outcomes
Research members. Respondents evaluated nine pairs of
hypothetical drugs, ﬁrst indicating which drug was “better,”
then indicating what they would recommend to a reimburse-
ment authority such as the National Health Service. Stated-
choice studies often obtain only paired-comparison
judgments.
Results: Parameter estimates from the initial paired-
comparison question indicate only incremental cost-
effectiveness ratio and number of affected patients inﬂuence
evaluations. These two factors have identical weights in the
second recommendation question, but all four factors were
considered in determining the recommendation threshold.
Our sample was more willing than NICE to accept trade-offs
between cost-effectiveness and other drug features and was
less concerned about cost-effectiveness ratios and informa-
tion uncertainty. Nevertheless, our sample was in agreement
with NICE about the importance of the number of patients
who would beneﬁt as a criterion for inﬂuencing adoption
recommendations.
Conclusion: This study demonstrates that including a ques-
tion allowing respondents the opportunity to reject both
alternatives in a forced-choice paired comparison can be
important for obtaining accurate preference estimates. Our
results demonstrate that SP methods offer a feasible means of
quantifying a broad set of valuations that incorporate the
preferences of patient, citizen, payer, and other stakeholder
groups.
Keywords: choice experiments, conjoint analysis, cost-
effectiveness threshold, NICE, stated-preference methods.
Introduction
In 1999, England and Wales established the National
Institute for Clinical Excellence (NICE) to provide the
National Health Service (NHS) with consistent, unbi-
ased, and objective assessments of health-care technol-
ogies such as pharmaceuticals and devices. Analysts
often speculate about the incremental cost per quality-
adjusted life-year (QALY) thresholds, which underpin
the recommendations made by NICE. Senior members
of NICE recently stated that NICE “rejects the use of
an absolute threshold for judging the level of accepta-
bility of a technology in the NHS for four reasons [1]:”
The reasons cited were a lack of an empirical basis for
setting a threshold, possible circumstances in which
NICE would want to ignore a threshold, the implica-
tion that efﬁciency has priority over equity, and the
potential that a threshold would discourage price
competition.
Devlin and Parkin [2] recently examined 33 NICE
recommendations. They modeled the probability that
a submission would be recommended for acceptance
as a function of the incremental cost-effectiveness ratio
(ICER), error bounds of estimates, number of therapy
beneﬁciaries, and availability of substitute treatments.
All of these factors appear to play a signiﬁcant role in
actual NICE decisions.
The aims of this study were to evaluate a two-stage
stated-preference (SP) elicitation format for assessing
threshold judgments and to compare the relative
importance of various drug-adoption criteria among a
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group of stakeholders with the implicit importance of
similar criteria observed in NICE recommendations.
The principal aim of this study was to illustrate
applying discrete-choice methods for eliciting pre-
ferences for technology adoption criteria, including
threshold values for cost-effectiveness ratios. This was
achieved by administering a two-stage, SP elicitation
question format to a sample of respondents who have
expertise in applying economic analysis to technology
adoption decisions. A secondary objective of this study
is to compare the criteria weights of a sample of indus-
try stakeholders with the results obtained with the
implicit NICE criteria weights estimated by Devlin and
Parkin.
Methods
Revealed and Stated Preferences
Revealed-preference (RP) data consist of observations
of actual decision-maker behavior. RP data thus indi-
cate how people choose among available alternatives
under real-world information and resource con-
straints. Choice-format conjoint or SP data consist of
responses to survey questions that ask subjects to
choose among hypothetical alternatives. Researchers
have used SP methods to quantify preferences for a
variety of market and nonmarket goods and services.
These include medical interventions, pharmaceutical
treatments, and environmental health risks [3–9].
Analysts generally prefer RP data for quantifying
preferences. RP data indicate willingness to accept real
sacriﬁces to obtain a desired outcome. Unfortunately,
RP explanatory variables of interest may have little or
no variation or may be confounded with other varia-
bles. SP methods give researchers control over the
experimental design, which ensures statistical variabil-
ity necessary to estimate utility weights for individual
features of choice alternatives. The major disadvantage
of SP methods is that they rely on hypothetical choices.
We usually have no direct means of testing external
validity and must assume that people actually would
make the same choices in a real setting that they say
they would make in the hypothetical setting [10].
SP methods recognize that choice alternatives have
value because of their characteristics or attributes. Peo-
ple have preferences for each attribute and are willing
to accept trade-offs among them. SP analysis examines
these trade-offs to assess the weight people assign to
various product attributes. Thus, an important advan-
tage of SP methods is that they can provide a value for
the individual features of alternatives as well as the
decision as a whole. Traditional preference-elicitation
methods such as concept testing or quality-of-life sur-
veys may provide little insight into the relative per-
ceived importance of speciﬁc attributes.
In addition, SP methods encourage subjects to
explore their preferences for various attribute combi-
nations through a series of judgments. This process
of explicitly trading off attributes encourages subject
introspection. Finally, SP allows analysts to devise
internal checks for attentiveness and consistency
because each subject provides answers to multiple
trade-off questions.
Survey Development
Implementing a valid and reliable SP study requires
accurate deﬁnition of technology features, or attributes
(an attribute is a qualitative characteristic of the prod-
uct, and a level is one of several values the attribute
may have—color and price are attributes; blue and $25
are levels). We have illustrated the method by employ-
ing the attributes used in the Devlin and Parkin study,
which also enables us to compare our SP estimates
with RP estimates derived from NICE recommenda-
tions. Levels for each attribute correspond approxi-
mately to distributions of the data in the original study
(we are grateful to the authors for providing us with
the data they used in their analysis). Although NICE
and similar organizations evaluate a broad range of
health technologies, we developed a survey speciﬁcally
for pharmaceutical evaluation criteria. As described
below, evaluating medicines is the primary area of
interest and expertise of our respondent sample.
Specifying three levels for each attribute allows us
to check for nonlinearity in marginal effects. An earlier
working paper by Devlin and Parker reported statisti-
cally insigniﬁcant results of budget impact. This anal-
ysis was not included in the published version of the
study, but we included this attribute in our survey.
Table 1 shows the approximate percentile distribution
of values for the four attributes: Figure 1 shows an
example of the two SP choice tasks. Many SP research-
ers believe that the choice format is the most reliable
elicitation format [11]. The choice format most closely
corresponds to real-world decisions, has a clear basis
in utility theory, and can be used to generate experi-
mental designs with known optimality properties. For
ease of comparison, note that uncertainty is displayed
as the range corresponding to the uncertainty factor
rather than the factor itself.
The ﬁrst question is a “forced-choice” comparison
between two hypothetical drugs. Although answers
to this question reveal relative evaluations among
attributes, they cannot indicate whether subjects
believe the value of a given attribute combination
exceeds some minimum threshold for a favorable reim-
bursement recommendation. The second question
thus indicates whether either or both drugs are above
that threshold. In a treatment-preference or market
research application, a forced-choice comparison ques-
tion alone would provide no information on intended
uptake. For example, Johnson et al. [12] conducted a
stated-choice survey of preferences for a diabetes-
reduction program in a sample of subjects with multi-
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ple risk factors for diabetes. Subjects who perceived
their risk to be high were willing to pay about $3200
for a program with given features, and subjects who
perceived their risk to be low (all subjects were actually
at high risk) were willing to pay about $1000 for the
same program features. From this information alone, it
is impossible to determine what the uptake would be.
The actual out-of-pocket costs and perceived incon-
venience of the program will determine the uptake
threshold value. Such information is not available
from a forced-choice trade-off question alone.
Experimental Design
Full-factorial experiments generate data based on all
possible combinations of attribute levels. Such designs
typically are impractical for SP surveys because sub-
jects’ cognitive and time limitations do not allow con-
sideration of a large number of proﬁles. For example,
a full factorial design of the four attributes with three
levels shown in Table 1 contains 81 (34) possible com-
binations. Subjects do not rate these options individu-
ally because it would clearly be an impossible task;
considered in pairs, the number of possible combina-
tions is 3240.
Most current marketing SP applications use an
approximately orthogonal design to reduce the
number of paired comparisons to the smallest number
necessary for efﬁcient estimation of utility weights
[13]. Huber and Zwerina [14] list the following three
properties of efﬁcient designs: level balance (levels of
an attribute occur with equal frequency), orthogonal-
ity (the occurrences of any two levels of different
attributes are uncorrelated), and minimal overlap
(cases where attribute levels do not vary within a
choice set should be minimized).
Practical design construction generally requires
trading off potential incompatibilities among these cri-
teria. For example, generating pairs from a strictly
orthogonal design often results in dominated pairs and
high levels of overlap. Nevertheless, Kuhfeld, Tobias,
and Garratt [15] show that it is possible to produce
efﬁcient designs that are neither balanced nor orthog-
Table 1 Attributes and levels
Attribute Deﬁnition
Distribution in Devlin and
Parkin data
Levels in experimental
design
ICER Cost per quality-adjusted
life-year gained in (£1000)
90%: 46 50
50%: 20 30
10%: 8 15
BURDEN Thousands of people
affected by the condition
90%: 1000 200
50%: 53 50
10%: 3 1
IMPACT Impact on health service
budget (£ million)
90%: 25 50
50%: 7 10
10%: 0 1
UNCERTAINTY Range of ICER divided by
ICER point estimate or mean
90%: 1.3  1.0
50%: 0.7  0.6
10%: 0.3  0.2
Figure 1 Example of conjoint choice task.
NICE, National Institute for Clinical Excellence;
QALY, quality-adjusted life-year.
Feature Drug A Drug B 
Cost per QALY 10,000 50,000 
95% Confidence interval for cost per QALY 1,000– 19,000 25,000– 75,000 
Annual number of patients who would benefit 1,000 50,000 
Annual total cost to National Health Service  10 million 50 million 
        
Please mark one box. 
A is better than B B is better than A 
    
Please mark one box. 
If I were advising an organization such as NICE, I 
would recommend approval of:  A only B only Both Neither 
1000  ≈ 1600  ≈  US$1500 
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onal. Such efﬁcient designs can be produced using an
iterative computer algorithm. The attribute levels for
Drug A and Drug B were determined using a similar
algorithm for constructing D-optimal experimental
designs for choice-format SP surveys [16]. Each subject
evaluated nine conjoint tasks similar to that shown in
Figure 1 [17].
Survey Administration
The sample frame for our survey included all attendees
at the 2002 European meeting of the International
Society for Pharmacoeconomics and Outcomes
Research (ISPOR). This group provided access to a
convenience sample of professionals who are familiar
with health economics in general and applications of
economic evaluation to technology-assessment deci-
sions in particular. We approached attendees during
coffee breaks and poster sessions, explained to them
the topic of the survey, that it would take about 10 min
to complete, and that the results would be presented in
a methods workshop on the last day of the conference.
We motivated recruitment by offering subjects entry
into a drawing for a Toshiba Pocket PC E740 ($600
value). One hundred ten subjects provided usable data
for analysis, but it is not possible to calculate the
response rate. Some respondents received more than
one questionnaire before ﬁlling one in and submitting
it. Using conventional criteria for a survey with nine
SP questions, this sample size is adequate to estimate
the parameters of interest with good precision [18].
Table 2 contains summary statistics for our sample.
We obviously can make no claim about the repre-
sentativeness of this intercept sample of the population
of ISPOR members. Subjects were self-selected and we
have no basis for analyzing the selection mechanism.
Nevertheless, there was no obvious, systematic refusal
pattern. Most ISPOR members are professionals
involved in the drug or other technology development
and evaluation process. Thus, conference attendees are
clearly interested in and knowledgeable about the
topic of the survey. Nevertheless, nearly two-thirds of
our sample worked for the pharmaceutical industry
and may be more inclined to favor more liberal drug-
adoption criteria. Although this sample clearly is
unrepresentative of the general population of health
experts, its members, nevertheless, are important
stakeholders in the drug-assessment process. Moreo-
ver, the primary objective of this study is to illustrate
applying SP methods to evaluate technology-
assessment criteria. The ISPOR convenience sample is
suitable for this purpose.
Conceptual Framework and Estimation
We obtain data from the ﬁrst question on paired com-
parisons regarding which drug is “better.” The second
question elicits a judgment about whether both, either,
or neither of the drugs would be recommended for
reimbursement. The content and interpretation of
these two sources of information is different and
requires different modeling strategies. We then pool
the data and estimate a third model that aggregates the
data from both questions. Pooling categorical data
requires controlling for differences in variance or scale
between data sets [19].
Comparison Model
Paired-comparison models lend themselves to analysis
using stochastic utility-maximization theory. Our
experimental design is a main-effects design that
doesn’t allow estimating interaction effects. Main-
effects designs are widely employed by SP researchers
because they are smaller and more tractable than
larger fractional factorial designs. Louviere [20] found
that main-effects models explain as much as 85% of
the variation in the data. The main-effects speciﬁcation
can accommodate nonlinear transformations of the
individual attributes. Speciﬁcation testing indicated
that utility is approximately linear for all attributes
within the range of levels speciﬁed. Respondents’
stochastic utility function for drug proﬁle j can be
expressed as a linear function of attributes:
Uj = αCERICERj + αBURBURDENj + αIMPIMPACTj + 
αUNCUNCERTAINTYj (1)
where ICER, BURDEN, IMPACT, and UNCER-
TAINTY are deﬁned in Table 1. The α coefﬁcients are
marginal-utility parameters that we interpret as rela-
tive importance weights. We use the term “utility” here
in the conventional ordinal-utility sense, not von Neu-
man-Morgenstern cardinal utility scaled between 0
and 1. Stochastic utility maximization postulates that
respondents will choose Drug A from a pair of alter-
natives A and B if UA − UB > εd, where εd is an error
term. Assuming a logistic error structure, the proba-
bility of choosing Drug A is conditional logit:
Table 2 Descriptive statistics
Category Count Percent
Sex
Female 40 33.6
Male 79 66.4
Academic degree
PhD 39 36.8
MS 21 19.8
MD 12 11.3
PharmD 10 9.4
Other 24 22.6
Country
North America 25 20.2
UK 20 16.1
Other Western Europe 54 43.5
Eastern Europe 13 10.5
Other 12 9.7
Afﬁliation
Industry 55 64.7
Academic, government, and consulting 30 35.3
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(2)
where X is the vector of drug attribute levels, β is a vec-
tor of parameter estimates, βI = αi/σd, and σd is the
standard deviation of εd. σd generally is not identiﬁable
in limited-dependent-variable models and is normal-
ized to one.
Recommendation Threshold Model
Subjects will advise accepting Drug A for reimburse-
ment if UA > δ + εt, or UA − δ > εt, where δ is a thresh-
old value equal to the utility of the status quo. The
probability of advising acceptance thus is also con-
ditional logit, where alternative 0 is the rejection
alternative:
(3)
and γ = {γICER, γUNC, γBUR, γIMP}, γI = αi/σt. Thus, our null
hypothesis is that the underlying structural parameters
are the same for both the comparison and recommen-
dation models. Estimates should differ only by a rela-
tive scale factor σd/σt.
Joint Model
Although variances are not identiﬁable in individual
models, we can identify the relative scale factor by
pooling the data from both the paired-comparison and
recommendation questions in a single joint model. We
estimate all models by the method of maximum like-
lihood. Estimates were obtained using GAUSS 4.0 Max-
Lik procedures (Aptech Systems, Inc., 2002, Black
Diamond, WA, USA). The log likelihood function for
the joint model is:
(3)
where j indexes individual stated choices for the com-
parison question, k indexes individual choices for the
recommendation question, σd is normalized at one,
and the relative scale factor μ = 1/σt.
Results
Parameter Estimates
Table 3 compares the three SP models described above.
ASC REJECT is the alternative-speciﬁc constant for
rejection and SCALE is the relative scale parameter for
the joint model. Other variables are deﬁned as above.
All parameters are statistically signiﬁcant at the 10%
level or better in the recommendation and joint mod-
els, but only ICER and BURDEN are signiﬁcant in the
comparison model. The recommendation and joint
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model parameters are quite similar except for
UNCERTAINTY, which is smaller and less signiﬁcant
in the joint model. All signiﬁcant parameters have
expected signs. The relative scale parameter is
inversely proportional to the variance, indicating that
the variance in the recommendation response is greater
than the variance in the comparison response.
The ICER and BURDEN parameters are equivalent
in both the comparison and recommendation models,
but the additional factors of IMPACT and UNCER-
TAINTY are inﬂuential in explaining recommendation
thresholds. Most stated-choice studies employ only a
paired-comparison question. Nevertheless, including
the second question in our study provides a more com-
plete measure of respondents’ evaluations of drug-
adoption criteria.
Figure 2 illustrates the sensitivity of the likelihood
of a positive recommendation to values of the explan-
atory variables using estimates from the joint model.
The ﬁgure plots the probability of advising a positive
recommendation for multiples of the experimental-
design mean value of each of the four factors, holding
the other factors constant at their means. All four gra-
dients cross at the average probability of 0.62. At this
point the multiple equals one so all factors are set to
their mean values of 31.7 for ICER, 89.1 for BUR-
DEN, 23.1 for IMPACT, and 29.7 for UNCER-
TAINTY. The probability decreases from 0.62 to 0.26
Table 3 Estimated utility coefﬁcients, SP models
Variables Paired comparisons Recommendation Joint
ICER −0.0516* −0.0496* −0.0567*
IMPACT −0.0048 −0.0207* −0.0171*
BURDEN 0.0083* 0.0082* 0.0087*
UNCERTAINTY 0.0020 −0.0075† −0.0047‡
ASC REJECT −2.0453‡ −2.0679*
SCALE 0.7355*
*Signiﬁcant at the 1% level.
†Signiﬁcant at the 5% level.
‡Signiﬁcant at the 10% level.
SP, stated preference.
Figure 2 Effect of attribute values on probability of a positive
recommendation.
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for ICER, increases from 0.62 to 0.77 for BURDEN,
decreases from 0.62 to 0.51 for IMPACT, and
decreases from 0.62 to 0.57 for UNCERTAINTY.
Thus, in relative probability terms, a doubling of the
ICER is more than twice as important as BURDEN,
about three times more important than IMPACT, and
nine times more important than UNCERTAINTY. The
gap widens for larger multiples of mean values.
SP Threshold Value per QALY
According to the recommendation model speciﬁed in
Equation 3, the probability of a positive recommenda-
tion is 0.5 when the utility of a proposed drug is equal
to the utility of the status quo. Holding other factors
constant at their mean values, the ICER threshold
value at which the probability of recommendation is
0.5 is £41,400, which is considerably higher than the
£30,000 cost per QALY often cited for the UK context.
Although we might expect the majority of this sample
to be supportive of a high threshold, the £30,000
threshold has no clear conceptual or empirical basis
[21–23]. Thus, it is unclear how biased a £40,000
threshold is relative to the socially optimal ICER. Fur-
thermore, using the parameters from the comparison
model, the ICER threshold value falls to about
£30,000, implying that the ICER may play different
roles in judgments regarding the relative value of drugs
and judgments regarding recommendations for
approval. This calculation was obtained by using the
joint-model estimate of the utility threshold parameter
multiplied by SCALE, and solving for the value of CER
that would give a probability of 0.5 relative to the res-
caled threshold utility, holding other factors at their
mean values.
The signiﬁcance of attribute parameters other than
ICER indicates subjects were willing to accept trade-
offs between ICER and other drug features. Thus the
threshold ICER value will vary, depending on these
other features. Figure 3 plots threshold estimates for
values of number of affected patients and budget
impact. As before, the threshold ICER is £41,400 for
the mean values of burden and impact. Nevertheless,
the effect on the threshold works in opposite directions
for the two attributes, and the ICER threshold is rel-
atively more sensitive to decreases in impact than to
increases in burden. Subjects were willing to accept a
more liberal ICER threshold when the number of
affected patients increases. For example, the accepta-
ble threshold increases 50% to about £60,000, when
the number of affected patients rises to 200,000. Con-
versely, subjects require a stricter ICER criterion when
budget impact rises. For example, the acceptable
threshold decreases by 75% to about £10,000, when
the budget impact increases to £100 million.
Comparison of RP and SP Estimates
Table 4 indicates that the differences between the Dev-
lin and Parkin RP and our SP estimates derived from
ISPOR members are quite striking. The sample of
ISPOR members evaluated ICER and UNCERTAINTY
as less important than the RP analysis of NICE recom-
mendations imply. Nevertheless, our sample was in
agreement with NICE about the importance of BUR-
DEN. Furthermore, Devlin and Parkin found no evi-
dence that NICE considered budgetary impacts in their
recommendation, although such impacts had a signif-
icant negative inﬂuence on our sample’s evaluations.
Figure 4 shows the positive recommendation prob-
ability gradient for NICE recommendations. Rawlins
and Culyer [1] observe that the inﬂections of the curve
at points A and B correspond to ranges below which
and above which the ICER clearly indicates acceptance
and rejection, respectively. NICE would need “special
reasons” to reject a technology with an ICER less than
A or to accept a technology with an ICER greater than
B. Rawlins and Culyer identify range A as £5000 to
£15,000 per QALY and range B as £25,000 to
£35,000 per QALY. Nevertheless, the Devlin and Par-
kin estimates based on actual NICE recommendations
suggest that A and B ranges are considerably higher,
about £10,000 to £30,000 and £40,000 to £60,000,
respectively.
Figure 3 Willingness to accept trade-offs among BURDEN (1000s of
patients), IMPACT (£ million), and ICER threshold.
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Table 4 RP and SP odds-ratio estimates*
Variables Devlin and Parkin RP Joint SP
ICER 0.8388‡ 0.9449†
BURDEN 1.0102‡ 1.0087†
UNCERTAINTY 0.3713‡ 0.9953§
IMPACT 0.9830†
ASC REJECT 0.1265†
*Devlin and Parkin report estimates as odds ratios for rejection. We have converted
their estimates to odds ratios for acceptance. Devlin and Parkin also include a dummy
variable, not reported here, for whether or not substitute treatments are available.
†Signiﬁcant at the 1% level.
‡Signiﬁcant at the 5% level.
§Signiﬁcant at the 10% level.
RP, revealed preference; SP, stated-preference.
Drug Adoption Criteria Preferences 309
The joint SP ICER odds-ratio estimate is statisti-
cally signiﬁcantly larger than the Devlin and Parkin RP
estimate (P = 0.0096). Figure 4 compares predicted
probability of a positive recommendation for the two
estimates. The £35,400 Devlin and Parkin threshold at
0.5 probability is somewhat less than the ISPOR mem-
bers threshold of £41,400. More importantly, the
NICE probability gradient is steeper, indicating that
NICE is much less willing to accept compromises
between ICER and other drug features compared with
our sample. Consequently the SP gradient lacks clear
inﬂection points A and B. As seen above, our sample
was more willing to accept trade-offs, thus were more
likely than NICE to recommend adopting proposed
drugs with an ICER greater than £33,000.
SP Willingness to Pay per QALY
Although the published version of Devlin and Parkin’s
study does not report budget-impact estimates, trade-
offs involving the budgetary burden of the drug and
the number of affected patients may provide additional
information on relative valuations. The money equiv-
alent of the increased utility of one QALY is the
decrease in budget expenditure that yields the same
increase in perceived utility. This value corresponds to
willingness to pay (WTP), although in this case,
respondents are acting as if they are spending out of
the public purse instead of their own.
(6)
The marginal utility of a £1 decrease in health-care
expenditures in the denominator of Equation 6 is sim-
ply the negative of the marginal disutility of a £1
increase in costs.
Assuming total cost (TC) is the same as budget
impact (adjusted for units), deﬁning ICER as TC/
QALYs, and using Equation 1, the marginal utility of
WTP
U QALYs
U TC
= ∂ ∂
-∂ ∂
an additional QALY and marginal disutility of an
additional £1000 in costs are, respectively,
(7)
(8)
Figure 5 plots the relationship between number of
QALYs gained per patient and WTP. The shape of the
function is a consequence of the squared term in the
denominator of Equation 7 and rescaling ∂U/∂QALYs
using a ratio. Total WTP increases at a decreasing rate
because incremental WTP is strongly diminishing in
QALYs per patient, with only QALYs less than one
yielding incremental WTP greater than £30,000.
These calculations impose strong conditions on the
observed trade-offs. Subjects did not actually see the
number of QALYs gained, although the efﬁcacy and
number of affected patients implied it. It is likely, as
noted above, that subjects anchored on the conven-
tional ICER threshold, which affects βCER and inﬂu-
ences both the implicit marginal utility of QALYs and
the marginal disutility of cost in Equation 6. Neverthe-
less, consistent with the predictions of economic the-
ory, the subjects’ willingness to accept trade-offs
among drug features implies a nonconstant value per
QALY that depends on the implied QALY beneﬁt
gained, as well as other drug features.
Discussion
Stated-choice surveys are used increasingly to elicit
patient, physician, and payer preferences for new
health technologies. This study illustrates the impor-
tance of eliciting both comparison and recommenda-
tion judgments in measuring such trade-off
preferences. We found signiﬁcant differences between
questions that elicited paired comparisons of drug fea-
tures and a follow-up question that elicited a recom-
∂
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Figure 4 Probability of a positive recommendation. RP, revealed prefer-
ence; SP, stated-preference.
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Figure 5 Willingness to pay per additional quality-adjusted life-year
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mendation judgment. This ﬁnding indicates that
paired-comparison data alone are insufﬁcient to char-
acterize factors that inﬂuence uptake decisions.
Our study ﬁnds strong evidence of declining WTP
per QALY. This result is consistent with empirical
studies that ﬁnd nearly universal downward-sloping
demand curves for market and nonmarket commodi-
ties. Several published and ongoing studies aim to esti-
mate a constant WTP per QALY. Our result and
economic reasoning suggest such an objective is incon-
sistent with preferences [24,25].
We also observe important differences between the
RPs of NICE and a sample of respondents working as
both producers and consumers of evidence for health-
technology adoption decisions. Although we make no
claim to the representativeness of this sample, either in
terms of the population of ISPOR members or a gen-
eral population, we have highlighted the potential for
signiﬁcant differences between groups regarding the
relative importance of features of new therapeutic
technologies. These importance weights are, in effect,
judgments about the relative social value of new health
technologies.
There are several limitations of our analysis. Per-
haps the most important limitation is that we cannot
generalize from our convenience sample to any partic-
ular stakeholder group. The sample is unrepresentative
in several respects. Despite the fact that most ISPOR
conference participants are likely to be familiar with
the methods and applications of economic appraisal in
health care, the possibility remains that some respond-
ents were not familiar with the particular topic of our
survey. The data were collected in 2002, which is con-
temporaneous with the Parkin and Devlin study, but
now is several years old. A replication of the study
might produce different results as a consequence of
changes in institutions and standards in the interven-
ing period.
Although NICE evaluates a wide range of health
technologies, this study focused on drugs only. This
strategy simpliﬁed the task of preparing respondents
for the judgment-elicitation questions, however, it also
limits the comparisons with actual NICE recommen-
dations, which do not focus only on pharmaceuticals.
We do not know whether and to what extent prefer-
ences are likely to differ depending on the nature of the
technology being assessed.
The fact that some of our respondents might be
biased in favor of higher ICER thresholds may be
regarded as a limitation of the study if their SPs are
consistent with a self-interested view of the drug-eval-
uation process. Nevertheless, we take no position on
the relevance or validity of this particular sample’s
judgments. We have no comparable measure of the
general public’s drug-evaluation preferences. A bal-
anced view of relevance would have to assess the
authoritative claims of NICE reviewers, as well.
Although NICE experts may be well qualiﬁed to eval-
uate the scientiﬁc evidence related to such technolo-
gies, their expertise does not necessarily extend to
assessing society’s willingness to accept trade-offs
among technology features. Rawlins and Culyer [1]
correctly observe that NICE experts “have no partic-
ular legitimacy to determine the social values of those
served by the NHS. . . . In the absence of other rele-
vant information, NICE will have to make its own
social value judgments and be held accountable for
them.” Considering the importance of NICE’s recom-
mendations to the NHS, it would be appropriate to
subject NICE’s explicit and implicit standards to a
public debate involving patients, taxpayers, and their
elected representatives.
Rather than leaving such important social judg-
ments to one group of health scientists and their advi-
sors, the time is right to quantify the public’s WTP for
the additional therapeutic beneﬁts offered by new
pharmaceuticals, devices, and other health technolo-
gies. As demonstrated here with one sample of stake-
holders, SP methods offer a feasible means of
quantifying a broader set of valuations that incorpo-
rate the preferences of patient, citizen, payer, and other
stakeholder groups. NICE and the National Co-
ordinating Center for Research Methodology are
sponsoring a series of valuation studies to provide an
empirical basis for this important public debate. (See,
e.g., National Co-ordinating Center for Research
Methodology [26]).
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